Fortune 500 animal health company Zoetis announced Wednesday it completed the previously announced acquisition of Basepaws, a privately held pet care genetics company, which provides pet owners with genetic tests, analytics and early health risk assessments that can help manage the health, wellness and quality of care for their pets.
The acquisition was first announced June 7, and financial terms of the transaction were not disclosed.
“When we first met Basepaws CEO Anna Skaya and the team, we were immediately drawn to their passion for pets and the role that genetic testing and data analytics can have in advancing animal care — a purpose that drives us every day,” Zoetis CEO Kristin Peck said in a statement. “The addition of Basepaws will enhance our portfolio in the precision animal health space and inform our future pipeline of petcare innovations. Working together, we can continue to provide veterinarians and pet owners with more comprehensive ways to proactively manage the health, wellness and quality of care for their animals.”